Ankylosing Spondylitis and Cancer Risk

Shiuan-Tzuen Su; Yung-Heng Lee; Po-Cheng Shih; James C-C Wei

doi:10.1111/1756-185X.70085

Ankylosing Spondylitis and Cancer Risk

Int J Rheum Dis. 2025 Jan;28(1):e70085. doi: 10.1111/1756-185X.70085.

Authors

Shiuan-Tzuen Su^{1

2}, Yung-Heng Lee^{3

4

5

6}, Po-Cheng Shih^{7

8}, James C-C Wei^{8

9

10}

Affiliations

¹ Department of Surgery, Chung Shan Medical University Hospital, Taichung, Taiwan.
² School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
³ Department of Orthopedics, Cishan Hospital, Ministry of Health and Welfare, Kaohsiung, Taiwan.
⁴ Institute of Medical Science and Technology, National Sun Yat-Sen University, Kaohsiung, Taiwan.
⁵ Department of Senior Services Industry Management, Minghsin University of Science and Technology, Hsinchu, Taiwan.
⁶ Department of Recreation and Sport Management, Shu-Te University, Kaohsiung, Taiwan.
⁷ Department of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan.
⁸ Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
⁹ Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan.
¹⁰ Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan.

PMID: 39835510
DOI: 10.1111/1756-185X.70085

Abstract

Chronic inflammation is a major characteristic of ankylosing spondylitis (AS) and is closely related to the mechanisms of cancer development. Persistent inflammatory responses can lead to DNA damage, gene mutations, and abnormal cell proliferation, all of which may increase the risk of cancer. We also explore the use of biologic therapy of AS and their potential cancer risks.

Keywords: TNFi; ankylosing spondylitis; cancer; inflammation.

Publication types

Review
Editorial

MeSH terms

Animals
Biological Products / adverse effects
Biological Products / therapeutic use
Genetic Predisposition to Disease
Humans
Neoplasms* / epidemiology
Prognosis
Risk Assessment
Risk Factors
Spondylitis, Ankylosing* / diagnosis
Spondylitis, Ankylosing* / drug therapy
Spondylitis, Ankylosing* / epidemiology
Spondylitis, Ankylosing* / immunology

Substances

Biological Products